Floatz logo

Tazemetostat

Recurrent Osteosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

58 Active assets in the Recurrent Osteosarcoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
(+)-VINCRISTINE
Milton S. Hershey Medical Center
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →